Isshiki et al. documented a successful case of refractory thymic carcinoma with high PD-L1 expression treated with pembrolizumab as a second-line therapy after three cycles of carboplatin plus nab-paclitaxel [18]. Here, CD274 is linked to thymic carcinoma.